Methotrexate for Central Serous Chorioretinopathy Treatment Trial
Information source: Hadassah Medical Organization
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Central Serous Chorioretinopathy
Intervention: Methotrexate (Drug); Delayed treatment (Drug)
Phase: Phase 2
Status: Not yet recruiting
Sponsored by: Edward Averbukh Official(s) and/or principal investigator(s): Edward Averbukh, MD, Principal Investigator, Affiliation: Hadassah Medical Organization
Summary
Central serous chorioretinopathy (CSC) is a disease of unknown origin however multiple
reports have indicated correlation of appearance of CSC with exposure to exogenous or
elevated levels of endogenous corticosteroid. Since the level of endogenous corticosteroids
is upregulated in many inflammatory conditions, control of the inflammation may be
beneficial in reducing this level thus eliminating the stimulus for CSC. Methotrexate (MTX)
is widely used to control different types of inflammation. The investigators are going to
try an escalating doses of MTX to treat CSC under full medical supervision.
Clinical Details
Official title: Phase 2 Study of Escalating Oral Methotrexate for Central Serous Chorioretinopathy
Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Optical Coherence Tomography indicating the level of central serous detachment
Detailed description:
Central serous chorioretinopathy (CSC) is a disease of unknown origin usually affecting the
center of the macula in adults of working age. Though previously the condition was
considered stress-related, multiple recent reports have indicated correlation of appearance
of CSC with exposure to exogenous or elevated levels of endogenous corticosteroid. Since the
level of endogenous corticosteroids is upregulated in many inflammatory conditions, control
of the inflammation may downregulate the endogenous steroids thus eliminating the stimulus
for CSC. Methotrexate (MTX) is widely used to control different types of inflammation. Few
short retrospective series of beneficial effect of MTX on CSC were reported recently. The
investigators are going to try an escalating doses of MTX to treat CSC under full medical
supervision in a prospective manner.
Eligibility
Minimum age: 20 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Central Serous Chorioretinopathy
Exclusion Criteria:
- Pregnancy
- Liver disease
- Kidney disease
- Steroid use
Locations and Contacts
Hadassah Hebrew Univercity Medical Center, Jerusalem 91120, Israel; Not yet recruiting Edward Averbukh, MD, Phone: +972-508946140, Email: edwaver@gmail.com Samer Khateb, MD, PhD, Phone: +972-542504857, Email: samerkhateb@gmail.com Samer Khateb, MD, PhD, Principal Investigator
Additional Information
Starting date: August 2012
Last updated: July 18, 2012
|